Essex Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Essex Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,135	Closed	-$1.02M	–	443
2020 Q4	$1.02M	Sell	19,135 -5,865	-23%	-$291K	0.13%	224
2020 Q3	$1.03M	Buy	+25,000	New	+$1.08M	0.15%	210
2019 Q1	–	Sell	-39,376	Closed	-$637K	–	480
2018 Q4	$637K	Sell	39,376 -656	-2%	-$12.7K	0.1%	239
2018 Q3	$831K	Buy	+40,032	New	+$630K	0.1%	253
2016 Q4	–	Sell	-16,647	Closed	-$530K	–	340
2016 Q3	$530K	Hold	16,647	–	–	0.09%	244
2016 Q2	$540K	Hold	16,647	–	–	0.09%	224
2016 Q1	$465K	Hold	16,647	–	–	0.08%	238
2015 Q4	$593K	Hold	16,647	–	–	0.09%	220
2015 Q3	$551K	Hold	16,647	–	–	0.09%	218
2015 Q2	$697K	Hold	16,647	–	–	0.11%	202
2015 Q1	$543K	Hold	16,647	–	–	0.08%	227
2014 Q4	$529K	Hold	16,647	–	–	0.08%	215
2014 Q3	$412K	Hold	16,647	–	–	0.06%	244
2014 Q2	$376K	Hold	16,647	–	–	0.06%	272
2014 Q1	$405K	Hold	16,647	–	–	0.06%	266
2013 Q4	$416K	Hold	16,647	–	–	0.06%	287
2013 Q3	$457K	Hold	16,647	–	–	0.07%	264
2013 Q2	$302K	Buy	+16,647	New	+$229K	0.05%	270

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Essex Investment Management's ACAD Position: Q1 2021 in Review

Essex Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 19,135 shares — an estimated $1.02M sold.

Essex Investment Management first reported a position in ACAD in Q2 2013 and held it in 18 quarters. The position peaked at $1.03M in Q3 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Essex Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Essex Investment Management sold 19,135 Acadia Pharmaceuticals shares in Q1 2021, an estimated $1.02M.
Essex Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 18 quarters.
Essex Investment Management's Acadia Pharmaceuticals position peaked at $1.03M in Q3 2020.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Essex Investment Management's 13F filing for Q1 2021, filed 12 May 2021.